Truist Financial Upgrades Jazz Pharmaceuticals Target Price to $205

Summary

Truist Financial has raised its price target for Jazz Pharmaceuticals (NASDAQ:JAZZ) from $200.00 to $205.00, maintaining a ‘buy’ rating. This suggests a potential upside of 64.75% from the current price. Other analysts have varied opinions, with Piper Sandler setting a target of $147.00 and the Royal Bank of Canada at $172.00. Jazz Pharmaceuticals’ stock opened at $124.43, with a market cap of $7.55 billion. The company reported a quarterly EPS of ($8.25), missing estimates, and has set FY 2025 guidance at 4.800-5.600 EPS.Market Beat

Impact Analysis

This is a company-level event focused on Jazz Pharmaceuticals. Truist Financial’s raised price target reflects confidence in the stock’s future performance, despite recent financial challenges, such as the EPS miss and significant R&D expenses related to the Chimerix acquisition.Reuters+ 2 The diverse range of target prices from different analysts highlights uncertainty and differing opinions on the company’s valuation.Market Beat The immediate impact might be a positive investor sentiment and potential upward movement in stock price, although skepticism remains due to the company’s current loss situation. Investors might explore opportunities in Jazz Pharmaceuticals if they agree with the positive outlook or compare it against perceived risks like competition and financial performance volatility.